Ultrasound Ablation for Essential Hypertension（FIM）

Inclusion Criteria: 1. Age≥18 and≤80 years old, no gender limitation; 2. Two or more antihypertensive drugs should be statically taken for at least 4 weeks before randomization and the prescribed dose should be ≥ 50% of the manufacturer's maximum dose， angiotensin-converting enzyme inhibitor (ACEI) (or angiotensin-Ⅱ receptor antagonist (ARB)) and calcium channel blocker (CCB) (or thiazide diuretic) are required to be used in combination. Blood pressure meets the following conditions: 1) office systolic blood pressure (SBP)≥150mmHg and\<180mmHg; 2) office diastolic blood pressure (DBP) ≥90mmHg; 3. 24-hour ambulatory systolic blood pressure: ≥135 mmHg and \<170 mmHg; 4. A recorded history of essential hypertension; 5. Understands the purpose of this study, and is willing to sign the Informed Consent and complete clinical follow-up. Exclusion Criteria: 1. Ineligible renal artery anatomy including : (1) multiple renal arteries, (2) main renal artery diameter \<4mm or length \<20mm, (3) renal artery stenosis \> 50% in the main renal artery, (4) atherosclerosis of the renal artery, renal artery aneurysm, fibromuscular dysplasia or calcification, (5) pre-existing renal stent, (6) single kidney 2. Estimated glomerular filtration rate (eGFR) \<45 mL/min/1.73 m2 3. Type Ⅰ diabetes mellitus or poorly controlled type Ⅱ diabetes mellitus (defined as plasma Hb1Ac≥ 9.0% or 24-hour urinary protein quantification \>1g/24h or proliferative retinopathy) 4. Postural hypotension 5. Recent vascular events: Experienced acute myocardial infarction, unstable angina, syncope, or cerebrovascular accident within 3 months of the screening period 6. Possible secondary hypertension 7. Respiratory support: The individual requires long-term oxygen support or mechanical ventilation other than nocturnal respiratory support for sleep apnea 8. Life expectancy \<1 year 9. Female who is pregnant, nursing, or planning to become pregnant 10. Subjects who are currently enrolled in another clinical trial and have not completed their primary endpoint 11. Subjects who are allergic to contrast medium 12. Subjects who are unsuitable for the trial ，because of poor patient compliance or other reasons judged by the investigator